iXgene Inc.
- Biotech or pharma, therapeutic R&D
iXgene Inc. is a Japan-based biotech developing a genome-edited iPSC-derived cell therapy platform for hard-to-treat solid tumors.
Our lead program, IXG-001, is an allogeneic iPSC derived NSC therapy designed to locally activate chemotherapy within the tumor microenvironment. It targets glioblastoma (brain tumor) by converting a systemically administered prodrug into a potent anticancer agent at the tumor site—enabling highly localized, antigen-independent cytotoxicity with minimal systemic exposure.
The genome-edited iPSC master cell bank has been established, with GLP safety studies and IND preparation underway. iXgene aims to begin a Phase 1/2a trial in Japan in 2026, followed by a global Phase 2 study.
We are currently raising our Series A2 and seeking global partners for licensing, co-development, and future pipeline expansion.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}